Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease
Paula T. Trzepacz(Eli Lilly (United States)), Constantine G. Lyketsos(Johns Hopkins University), Linda B. Tabas(Eli Lilly (United States)), Thomas J. Konechnik(Eli Lilly (United States)), Jeffrey L. Cummings(University of Nevada, Las Vegas), Curtis Chang(Eli Lilly (United States)), Ellen B. Dennehy(Eli Lilly (United States)), Tammy Forrester(Eli Lilly (United States)), Catherine L Shuler(Eli Lilly (United States)), Brian A. Willis(Eli Lilly (United States))
Cited by 51
Related Papers
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
|Nature Genetics|2011|2k
Mood Disorders in the Medically Ill: Scientific Review and Recommendations
|Biological Psychiatry|2005|1.1k
The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation
|Psychological Medicine|2004|989
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
|New England Journal of Medicine|2007|925
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
|Nature reviews. Neuroscience|2021|493